Compare Cytokinetics Inc (CYTK) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Upwork Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: Cytokinetics Inc is far larger — about 8.1× Upwork Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Upwork Inc for 38 Days on average.
| CYTK | UPWK | |
|---|---|---|
Market Cap | $8.62B | $1.07B |
Volume | 2,594,626 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $87.26 | $22.11 |
52-Week Low | $54.76 | $7.84 |
Typical Hold Time | 19 Days | 38 Days |
Enterprise Value | $8.72B | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
UPWK trades at $8.57, up 2.02% today, but the technical outlook is bearish with resistance near $9. The company reported Q2 2026 earnings that beat estimates, with revenue of $191.7M and adjusted EBITDA of $64.1M (MarketBeat, August 10, 2026), but issued weak guidance causing a 13% stock drop (Invezz, August 11, 2026). Fundamentals show strong profitability with a 77.21% gross margin and a P/E of 10.99, though net income declined to $115.43M in 2025 from $216M in 2024.
The stock presents a mixed outlook: valuation appears attractive with analyst consensus target of $9.64 (12.5% upside), but risks include AI-driven disruption to freelance demand, insider selling, and ongoing securities fraud investigations (GlobeNewswire, September 2026). Investor sentiment is cautious despite a majority buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
